Human B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Human B7-H3 does not bind any known members of the CD28 family of immunoreceptor. However, B7-H3 has been shown to bind an unidentified counter-receptor on activated T cells to co-stimulate the proliferation of CD4+ or CD8+ T cells. B7-H3 has also been found to enhance the induction of primary cytotoxic T lymphocytes and stimulate IFN-gamma production.
Recombinant Human B7-H3 produced in HEK293 cells is a polypeptide chain containing 450 amino acids with C-terminal human IgG1 Fc fragment. A fully biologically active molecule, rhB7-H3 has a molecular mass of 62-65 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript.